- Home
- CRON vs KALV Comparison
CRON vs KALV Comparison
Compare CRON & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | KALV |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.8M | 1.0B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRON | KALV |
|---|---|---|
| Price | $2.62 | $26.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 2.3M | ★ 5.0M |
| Earning Date | 05-11-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $146,587,000.00 | $50,000,000.00 |
| Revenue This Year | $26.34 | $185.42 |
| Revenue Next Year | $15.53 | $59.23 |
| P/E Ratio | $65.63 | ★ N/A |
| Revenue Growth | 24.63 | ★ 495.66 |
| 52 Week Low | $1.84 | $9.83 |
| 52 Week High | $3.43 | $26.85 |
Technical Indicators
Market Signals| Indicator | CRON | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 74.87 |
| Support Level | $2.47 | $14.45 |
| Resistance Level | $2.73 | N/A |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 16.67 | 54.55 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.